TCGA-90-7767-01A-11R-2125-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.580
- G2M_CHECKPOINT+0.530
- MYC_TARGETS_V1+0.500
- INTERFERON_ALPHA_RESPONSE+0.450
- MITOTIC_SPINDLE+0.450
- MYC_TARGETS_V2+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INTERFERON_GAMMA_RESPONSE+0.350
- WNT_BETA_CATENIN_SIGNALING+0.340
- DNA_REPAIR+0.310
Top 10 suppressed
- XENOBIOTIC_METABOLISM-0.330
- COAGULATION-0.280
- BILE_ACID_METABOLISM-0.220
- FATTY_ACID_METABOLISM-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
- ESTROGEN_RESPONSE_EARLY-0.150
- ESTROGEN_RESPONSE_LATE-0.150
- ADIPOGENESIS-0.120
- P53_PATHWAY-0.110
- PEROXISOME-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-7699-01A-11R-2125-07 | — | cohortSQ1 | 0.860 |
| 2 | SRR934774 | — | — | 0.840 |
| 3 | TCGA-22-5480-01A-01R-1635-07 | — | cohortSQ1 | 0.838 |
| 4 | TCGA-ZF-AA54-01A-11R-A39I-07 | — | — | 0.817 |
| 5 | SRR934902 | — | — | 0.815 |
| 6 | 8F64E7A6-DEE2-426E-B843-DE4D73ECD667 | — | — | 0.811 |
| 7 | 6A30D8D0-DDB8-4B34-8BCB-46986144F551 | — | — | 0.804 |
| 8 | SRR934757 | — | — | 0.803 |
| 9 | SRR934775 | — | — | 0.791 |
| 10 | GSM5359424 | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |